Introduction
Rheumatoid arthritis (RA) is an autoimmune disease which causes chronic systemic joint inflammation. RA patients experience swollen and painful joints which seriously impact their normal well-being. About 1% of the population worldwide is currently affected by RA (Gibofsky, 2012) . The immune cells attack RA joints by inducing the release of cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukins at the synovial membrane, leading to the initiation of angiogenesis and proliferation of the synovial fibroblasts which causes the formation of pannus (Holmdahl et al., 2014) .
According to the European League against Rheumatism (EULAR) and American College of Rheumatology (ACR), disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and sulfasalazine are the primary medication for the patients soon after the onset of RA (Singh et al., 2015; Smolen et al., 2013) while cocktails of DMARDs and glucocorticoids are given as the substitutes when the therapeutic effect of initial prescription wanes off (f Smolen et al., 2013) . The medical regimens for RA patients keep on changing not only due to the reduction of their beneficial effects over time, their adverse side effects which cause morbidity and mortality in patients are seriously considered as well (Singh et al., 2015) . Due to the drawbacks in the currently available treatments for RA, new drug discovery is of research interest in order to offer patients with more choices of drugs other than the three main RA prescriptions (Quan et al., 2008) , with fewer or none adverse effects.
Boesenbergia rotunda (L.) Mansf., also known as fingerroot, is a rhizomatous plant species in Zingiberaceae family which had long been established as a medicinal plant family, commonly found in the Southeast Asian countries and tropical rainforests. (Basak et al., 2010) . The rhizomes of Boesenbergia rotunda (L.) Mansf. had been traditionally used as spices in cooking and medicines to relieve pain and inflammation such as peptic ulcers, allergy, and gout (Tewtrakul et al., 2009) . Since Boesenbergia rotunda (L.) Mansf. serves as the traditional medicine in a wide range, intensive studies were carried out to evaluate its therapeutic effect from different aspects, such as antiulcer (Abdelwahab et al., 2011) , hepatoprotective, (Mahmood et al., 2010; Salama et al., 2013) , Helicobacter pylori inhibition (Bhamarapravati et al., 2006) etc.
Pharmacological studies proposed that Boesenbergia rotunda (L.) Mansf. possesses therapeutic effects for chronic inflammatory diseases such as periodontitis and cancer (Gwon and Hwang, 2009; Hong et al., 2002) . Cardamonin (2′,4′-dihydroxy-6′-methoxychalcone) is an active compound isolated from Boesenbergia rotunda (L.) Mansf. and was previously reported to possess potent anti-inflammatory effect provided the evidence that it was able to inhibit the secretion of TNF-α from induced RAW 264.7 cells as well as the production of other proinflammatory mediators in whole blood (Ahmad et al., 2006) . Besides, an in vivo study demonstrated that cardamonin possesses effective anti-nociceptive activity in acute inflammatory pain model (Park et al., 2014) . Based on the extensive molecular work on cardamonin which yielded favorable anti-inflammatory results, it has led to the present study which aims to investigate the anti-arthritic effect of cardamonin on CFA-induced RA rat model.
Materials and methods

Plant material
The fresh rhizomes of Boesenbergia rotunda (L.) Mansf. (5 kg) were commercially purchased from the local market in Serdang, Selangor, Malaysia and were authenticated by a resident botanist at the Institute of Bioscience, Universiti Putra Malaysia (IBS, UPM), Malaysia. A voucher specimen (SK1780/10) was deposited at the Herbarium, Laboratory of Natural Products, IBS, UPM and small part of the rhizomes was cultivated in the Medicinal Plant Garden, IBS, UPM for future reference.
Extraction and isolation
The fresh rhizomes of Boesenbergia rotunda (L.) Mansf. were sliced into small flat pieces and dried under shadow for one week. The dried rhizomes were ground in to fine powder by using domestic food processor. The dried powder 2.5 kg was dissolved in distilled methanol for two-three days. The methanolic extract was filtrate and concentrate on rotary evaporator to obtained 255 g crude extract. The methanolic extract was subjected to solvent-solvent extraction. The crude methanolic extract was dissolved in 250 ml distilled water and transferred into separating funnel. About 150 ml of hexane was added into aqueous layer and subsequently extracted with chloroform, ethyl acetate and butanol. The chloroform layer finally passed over sodium sulfate anhydrous to remove the moisture. The chloroform extract was subjected to flash column chromatography by using ethyl acetate and hexane as eluents. Finally, the compound was purified from chloroform extract and identified as cardamonin ( Fig. 1 ) with 98.9% purity after performing the detailed spectroscopic techniques. 
Animals
The animals used in this study were male Sprague Dawley rats at about 6-8 weeks old, weighing approximately 200-250 g, housed under 12-h light/dark cycle at the animal housing facility of Faculty of Medicine and Health Sciences, Universiti Putra Malaysia for 1 week prior to the experiment with access to food and water ad libitum. The rats were acclimatised to the laboratory condition for at least 1 d before the experiment. The experiment were conducted in accordance with the current guidelines for the care of laboratory animals as well as the ethical guidelines for investigations of anti-arthritic activity in conscious and non-conscious animals, approved by the Animal Ethical Committee, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (Approval number: UPM/FPSK/PADS/BR-UUH/00504). The number of animals and the amount of noxious compounds used were minimum and just at necessary to demonstrate the effects of the drug treatment.
Chemicals
Complete Freund's adjuvant (CFA, 1 mg of heat-killed and dried Mycobacterium tuberculosis in mixture of 0.85 ml paraffin oil and 0.15 ml of mannide monooleate), dexamethasone, dimethyl sulfoxide (DMSO), and Tween 20 were purchased from Sigma Aldrich, Germany while OSTEOMOLL ® was purchased from Merck, USA. Enzyme-linked immunosorbent assay (ELISA) kits were purchased from R & D Systems, USA. The vehicle of cardamonin was prepared by mixing Tween 20, DMSO, and distilled water following the ratio of 5:5:90.
Sub-chronic 28-d toxicity test of cardamonin
The method described by Haruna (Haruna, 2014) and Organisation for Econimic Co-operation and Development (OECD) test guideline NO. 407 (OECD, 1994) was used with minor modification to determine the safe administration of cardamonin. Daily dosages of cardamonin (5.0 mg/kg, i.p.) were administered to a group of 6 healthy male Sprague Dawley rats while the control group only received vehicle (10 ml/kg, i.p.) for 28 days to compare the possible difference between rats administered with and without cardamonin. With free access to food and water, behavioral parameters such as convulsion, hyperactivity, food and water intake, loss of weight, as well as signs of toxicity and mortality were observed daily throughout the treatment period.
Induction of CFA-induced RA and treatment protocol
The study protocol used in this experiment was in accordance to the method demonstrated by Patil et al. (2011) with minor modification. Arthritis-inducing procedure was carried out on the rats (n=6) through intraplantar (i.pl.) injection of CFA (0.1 ml) at the right hind paws. Nine days after arthritis induction, different daily treatment dosages of cardamonin (0.625, 1.25, 2.5, and 5.0 mg/kg) were administered for 21 days through intraperitoneal (i.p.) injection. The group of positive control was given 3.0 mg/kg of dexamethasone while the negative control group was given only vehicle. CFA-induced paw edema, mechanical allodynia, and thermal hyperalgesia were evaluated at O OH HO OCH 3 European Journal of Pharmacology 794 (2017) 127-134 three-day interval throughout the experiment. On the 31st day, the rats were killed and whole blood was collected via cardiac puncture. The schematic timeline of the protocol is depicted in Fig. 2 .
CFA-induced paw edema test on cardamonin
The RA-induced paw edema test was conducted according to the method described by Choi et al. (2005) with slight modifications. The CFA-injected paw of the rats were marked at the tibio-tarsal junction and the paw volume was measured by dipping the marked paw into a liquid container of a plethysmometer (Model 7140, UgoBasile, Italy) before CFA injection as the initial volume, and at every three-day intervals throughout the experiment as the final volume. The paw volume was recorded in the unit of millilitre (ml). The paw volumes were measured in triplicate to obtain the mean paw volumes. The degree of inflammation was quantified by the difference between the mean final paw volume and the mean initial paw volume.
CFA-induced mechanical allodynia test on cardamonin
Mechanical allodynia in the CFA-induced RA rats were evaluated through von Frey hair test using electronic von Frey anesthesiometer (IITC 2393, Bioprobes Ltd., Hong Kong), according to the method previously described with slight modifications (Celerier et al., 2006) . The rats were placed in a transparent chamber with a wire grid bottom in which the von Frey filament could pass through and touched the rat paws. Rats were allowed to acclimatize for 5-10 min before testing. Mechanical force (g) was delivered through the von Frey filament onto the convex surface of the right hind paws. Rats would withdraw, shake or lick their right hind paws when the force of the semi-flexible filament applied had reached the nociceptive threshold. The mechanical force that caused paw withdrawal response was recorded before CFA injection as the initial force, and at every three-day intervals throughout the experiment as the final force. The degree of mechanical allodynia was quantified by the force changed between the final force and the initial force.
CFA-induced thermal hyperalgesia test on cardamonin
The nociceptive responses of the rats to thermal stimuli were tested using the plantar test instrument (Model 37370, Ugo Basile, Italy) according to the method previously described with slight modifications (Celerier et al., 2006; Hargreaves et al., 1988) . Experimental rats were placed in a transparent chamber with a glass floor and allowed to acclimatize for 5-10 min before testing. An infrared heat source was positioned under the glass floor beneath the right hind paw of a rat to be tested. When the rat lifted or licked its right hind paw, the withdrawal latency of the paw was shown and recorded automatically at the meter. The cut-off time for this test was set to be 20 s to prevent damage to the paw tissue. The paw withdrawal latency was recorded before CFA injection as the initial latency, and at every three-day intervals throughout the experiment as the final latency. The mean paw withdrawal latencies for the right hind paws were taken from three trials at 5-10 min intervals to prevent thermal sensitization. The degree of thermal hyperalgesia was quantified by the latency change between the mean final latency and the mean initial latency.
2.10. Effect of cardamonin on plasma level of TNF-α, IL-1β and IL-6 in CFA-induced rats Plasma was collected by centrifuging the EDTA tubes containing whole blood of the killed rats at 963 g (4°C) for 10 min. The ELISA kits (R & D Systems, USA) were used to identify the level of tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) in the blood plasma of the rats. The ELISA protocols were generally the same for these three cytokine kits, in which plasma dilution was not needed. First, 50 μl of assay diluent was added to each well, followed by the addition of 50 μl of standard, control, or sample per well mixed well by gentle tapping. After 2 h incubation at room temperature, each well was aspirated and washed for five times with wash buffer. The plate was then blotted against clean paper towels to remove remaining wash buffer. Immediately after that, 100 μl of conjugate was added to each well and the plate was incubated for 2 h at room temperature. After the washing step, 100 μl of substrate solution was added to each well. Next, the plate was incubated in a dark place for 30 min at room temperature. Finally, 100 μl of stop solution was added into each well and thorough mixing was done by gentle tapping the plate. The optical density of each well was determined using a microplate reader set to 450 nm and the wavelength correction was set to 540 nm. The raw data were analyzed using MyAssays Analysis Software Solutions.
Histological analysis on rat paws
The right hind paw of the killed rats was harvested for histological examination. The paws were fixed in 10% formalin and decalcified for 72 h in OSTEOMOLL®. The paws were then immersed in 5% aqueous sodium bicarbonate for two h to restore basophilic staining and rinsed well with distilled water before being proceeded to histological processes which include dehydration, clearing, and infiltration (Bancroft and Gamble, 2008 ). The paw samples were then embedded in paraffin wax and sectioned at 3 µm. Haematoxylin and eosin (H & E) sections of each paw were viewed under the microscope (LEICA DM2500, Germany) with installed camera (LEICA DFC420C, Germany). The interphalangeal joints were scored 0-3 as described in Table 1 (Haleagrahara et al., 2013; Lee et al., 2008) . The least severe condition would have a total score of 0-1 while the most severe condition of the joint would have a total score of 9-10.
Statistical Analysis
The data were expressed in mean ± standard error of mean (S.E.M.) of 6 rats. The data of RA-induced paw edema, mechanical allodynia and thermal hyperalgesia test were analyzed using two-way analysis of variance (ANOVA), followed by Bonferroni post hoc test while the data from ELISA were analyzed using one-way ANOVA, followed by Daily treatment (i.p.) Fig. 2 . Timeline for the anti-arthritic study.
Table 1
The scoring system for histological analysis of the harvested joints. (Haleagrahara et al., 2013; Lee et al., 2008 Dunnett's post hoc test. Histological scoring was analyzed using Kruskal-Wallis test, and followed by Dunn's post hoc test, unless otherwise stated. The results were considered significant when P < 0.05.
Results
Sub-chronic 28-d toxicity test on cardamonin
No mortality was reported at 5.0 mg/kg of cardamonin (i.p.) daily treatment for 28 days in rats. During the observation period, the animals did not show any signs of convulsion and abnormal behaviours. This result indicates that cardamonin has low toxicity profile.
CFA-induced paw edema test on cardamonin
The results depicted in Fig. 3(A) demonstrate that intraperitoneal administration of cardamonin (0.625, 1.25, 2.5, and 5.0 mg/kg) exhibited statistically significant (P < 0.05) and dose-related inhibition in the paw inflammation induced with CFA. 2.5 and 5.0 mg/kg of cardamonin caused significant reduction (P < 0.05) in the paw volume starting from Day 21. Meanwhile, 1.25 mg/kg started to show significant reduction (P < 0.05) in paw volume on Day 27 and 0.625 mg/ kg only showed significant reduction (P < 0.05) on Day 27. Treatment with 3.0 mg/kg dexamethasone demonstrated steady significant reduction (P < 0.05) in the paw volume from Day 12 until Day 30.
CFA-induced mechanical allodynia test on cardamonin
The results presented in Fig. 3(B) show that daily dosages of cardamonin (1.25, 2.5, and 5.0 mg/kg), given intraperitoneally, caused a statistically significant (P < 0.05) increase in the mechanical allodynia threshold in the inflamed rat paws. Only the lowest dose (0.625 mg/kg) of cardamonin showed no significant difference compared with negative control. Dexamethasone (3.0 mg/kg, i.p.) was used as the positive control and exhibited significant (P < 0.05) inhibition as compared with negative control.
CFA-induced thermal hyperalgesia test on cardamonin
The results showed that administration of cardamonin (0.625, 1.25, 2.5, and 5.0 mg/kg) via intraperitoneal route produced a significant (P < 0.05) and dose-dependent anti-hyperalgesic activity in induced RA rat model as depicted in Fig. 3(C) . Both the highest dose of cardamonin (5.0 mg/kg) and the positive control (3.0 mg/kg dexamethasone) caused significant reduction (P < 0.05) in CFA-induced thermal hyperalgesia in rat paws starting from Day 15. Meanwhile, 1.25 and 2.5 mg/ kg of cardamonin started to show significant inhibition (P < 0.05) in thermal hyperalgesia on Day 24 whereas the lowest dosage (0.625 mg/ kg) only demonstrated significant values (P < 0.05) on Day 30.
3.5. Effect of cardamonin on plasma level of TNF-α, IL-1β and IL-6 in CFA-induced rats Fig. 4 (A) demonstrated that only 0.625 mg/kg of cardamonin exhibited statistically significant (P < 0.05) reduction in the plasma level of TNF-α in the RA-induced rats. Intraperitoneal administration of cardamonin for 0.625, 1.25, and 2.5 mg/kg significantly (P < 0.05) reduce the plasma level of IL-1β as portrayed in Fig. 4(B) . As for Fig. 4(C) , cardamonin showed a reverse dose-dependent result, 0.625, 1.25, and 2.5 mg/kg of cardamonin significantly (P < 0.05) reduce the plasma level of IL-6 in the RA-induced rats. The positive control dexamethasone (3.0 mg/kg, i.p.) exhibited similar significant (P < 0.05) reduction as compared with negative control..
Histological analysis on rat paws
Histological slides exhibited in Fig. 5 showed notably growth of pannus in the negative control group while there was no sign of prominent growth of pannus in cardamonin-treated (0.625, 1.25, 2.5, and 5.0 mg/kg, i.p.) as well as dexamethasone-treated (3.0 mg/kg, i.p.) groups. The results for mean histological scoring showed that intraperitoneal administration of cardamonin (1.25 and 5.0 mg/kg) had significantly (P < 0.05) inhibit the narrowing of joint space, synovial hyperplasia, fibrosis and cartilage erosion as portrayed in the bar graph in Fig. 5 . The positive control, dexamethasone (3.0 mg/kg, i.p.), showed similar significant (P < 0.05) difference in the histological scoring as compared with negative control. In terms of the joint analysis scoring system, the arthritis control rats mostly showed severe arthritic characteristics (score 2-3), and the cardamonin-treated group F.-L. Voon et al. European Journal of Pharmacology 794 (2017) 127-134 showed moderate severity (score 0-2), while the dexamethasonetreated group showed the least severity in arthritic condition (score 0-1).
Discussion
In the present study, our findings demonstrated that cardamonin possesses inhibitory effect on rheumatoid arthritis condition in CFAinduced rats. Administration of cardamonin significantly reduced paw edema, arthritis scores, thermal hyperalgesia and mechanical allodynia observed in RA-induced rats. ELISA results also demonstrated that cardamonin significantly suppressed plasma level of pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6 compared with those in the normal control group.
The preliminary sub-acute toxicity test done on the highest dose of cardamonin in this study (5.0 mg/kg) showed no occurrence of death or abnormal behaviour during the period of observation. This result indicates that 5.0 mg/kg of cardamonin might have a reasonably low toxicity profile and should be regarded as safe compared with the currently available drugs for RA such as methotrexate, chloroquine and hydroxychloroquine. In previous study, continuous oral administration of methotrexate for 28 days led to histopathological lesions in the kidney and liver of the experimental rats besides negatively impacting the body weight as well as the normal physiological functions of the animals (Patel et al., 2014) . Chloroquine is another DMARD for RA treatment which completely altered the outer retinal layer of the mice after daily intraperitoneal administration for 62 days, indicating its potential of causing retinal toxicity (Gaynes et al., 2008) . Furthermore, daily oral administration of sulfasalazine for 14 days led to increased oxidative stress shown by the stress markers in the kidney and liver of the Sprague-Dawley rats, which is the mechanism of nephro-and hepatotoxicity (Linares et al., 2009 ).
The rat model of complete Freund's adjuvant (CFA)-induced RA was chosen for this study as it is an established and extensively used RA model in pharmaceutical research for the evaluation of the effectiveness of new compounds on inflammation and pain in RA (Bendele et al., 1999) . CFA-induced RA rat model mimics the pathological features occurring in human such as robust polyarticular inflammation, hypersensitivity to heat and mechanical stimuli, as well as deterioration of the joint structures (Bendele, 2001) . The mycobacterial components in the CFA cause T-lymphocytes to elicit strong immune response in the rat paws after the intraplantar injection (Billiau and Matthys, 2001 ). The T-lymphocytes interact with dendritic cells, monocytes, and macrophages to trigger the production of the predominant proinflammatory cytokine, TNF-α, as well as IL-1β and IL-6 in the synovial membrane (Tran et al., 2005) . TNF-α promotes inflammation through autocrine and paracrine stimulation and causes the release of other pro-inflammatory cytokines, including IL-1β and IL-6. TNF-α and other cytokines stimulate fibroblasts to express adhesion molecules which results in increased leukocytes transport to the inflammatory sites (Osborn et al., 1989) . In addition, these cytokines induced the production of chemokines such as IL-8 and monocyte chemotactic protein-1 (MCP-1) which attract the inflammatory cells like neutrophils and monocytes to the inflame paws (Taylor et al., 2000) . The inflammatory cells release pro-inflammatory mediators which lead to vasodilation and infiltration of more immune cells into the joint cavity (Taylor et al., 2000) .
In the present study protocol, 3 rats were randomly killed on Day 9 after the intraplantar administration of CFA, and the histological tissues of the rat joints showed proliferating synovial membrane as depicted in Fig. 5 , which supported the establishment of RA in the RA rat model as demonstrated by Bendele (2001) . Daily treatments were given to the rats starting on Day 9 in order to observe the therapeutic effects of cardamonin on the RA-induced rats. Cardamonin showed significant suppression upon CFA-induced paw edema in rats. Reduction of paw edema was possibly due to the suppression of proinflammatory cytokines released into the inflamed area as cardamonin was previously shown to suppress the synthesis of TNF-α through the inhibition of nuclear factor κB (NFκB) in which NFκB acts as the transcription factor to the genes related to RA, including TNF-α, IL-1β, and IL-6 (Ahmad et al., 2006) .
In the histological analysis, the growth of pannus was present in negative control group, whereas there was no sign of pannus growth in cardamonin-treated groups. This indicated that reversals of synovial tissue proliferation in the RA-induced histological joint changes were observed in the cardamonin-treated rats. The observed protective effects may be due to the structure of cardamonin, categorized under polyphenols, which are proven to be able to modulate the immune function by regulating the epigenetic mechanisms (Cuevas et al., 2013) . Besides, the reduction of TNF-α and IL-1β by cardamonin was able to cause a decrease in the expression of VEGF, the angiogenesis factor for vascular proliferation of the synovial membrane in RA rat joints (Paleolog et al., 1998) . Overall, the histological sections portrayed that cardamonin was able to inhibit the progression of the joint structure deformity in the rat model of CFA-induced RA.
The result of ELISA test showed that cardamonin has lowered the systemic pro-inflammatory cytokines levels of TNF-α, IL-1β, and IL-6 in the RA-induced rats. As shown in Fig. 4 , cardamonin significantly inhibits plasma level of IL-1β, IL-6 and TNF-α. IL-1β is secreted mainly by macrophages in the pathogenesis of RA and it acts as a paracrine messenger which induces the initiation of biological actions in other immune cells (Kay and Calabrese, 2004) . IL-6 is another vital cytokine in RA which induces the production of inflammatory cells such as B lymphocytes in the inflammatory process (Guerne et al., 1989) and simultaneously promote joint destruction via stimulating vascular endothelial growth factor (VEGF)-induced pannus formation as well as osteoclast maturation (Srirangan and Choy, 2010 ). The present result indicated that cardamonin has higher potency in suppressing the plasma level of IL-1β and IL-6 than TNF-α, which led to the inhibition of paw edema, mechanical allodynia, as well as thermal hyperalgesia. Cardamonin might have directly inhibited the action of systemic IL-1β and IL-6 in the disease progress in RA rats or indirectly through inhibiting the production of IL-1β and IL-6 from the immune cells.
Moreover, inflammation in the RA-inflicted joints induced central sensitization, marked by the development of hypersensitivity to mechanical and thermal stimuli, known as allodynia and hyperalgesia. Intraplantar administration of CFA in the experimental rats caused sustained microglial activation and delayed astrocyte activation, together with the up-regulation of TNF-α, IL-1β, and IL-6 (Raghavendra et al., 2004) . Activated microglial cells and astrocytes are able to release pro-inflammatory cytokines and thus enhancing the expression of these cytokines in the CNS (Aloisi, 1999) . Activation of both microglial cells and astrocytes may amplify the transmission of nociceptive information from the arthritic joints, possibly through the release of TNF-α, IL-1β, and IL-6 which interrupt the BBB by disorganising the cell-cell junctions, and cause the increased of permeability in BBB (Minagar Fig. 5 . Histological slides of joint morphology: The rat randomly killed on Day 9 to confirm the establishment of RA; Negative control; 3 mg/kg dexamethasone; 0.625 mg/kg cardamonin; 1.25 mg/kg cardamonin; 2.5 mg/kg cardamonin; and 5 mg/kg cardamonin (AC: articular cartilage; JC: joint cavity; P: pannus; PSM: proliferating synovial membrane; SM: synovial membrane) H & E x50. The bar graph shows means of total histological scoring for the joint morphology. Values are expressed as mean ± S.E.M. (n=6) in each group. The asterisks denote the significant level as compared with control, *P < 0.05 with Kruskal-Wallis test, followed by Dunn's post hoc test.
and Alexander, 2003; Raghavendra and DeLeo, 2003) . Central sensitization occurs when immune cells infiltrate into the CNS through BBB, causing the increase production of inflammatory mediators that amplify the excitability of neurons within CNS, resulting in allodynia and hyperalgesia (Minagar and Alexander, 2003; Raghavendra et al., 2004) .
The present study revealed that cardamonin was able to reduce the mechanical allodynia in the inflamed rat paws. This can be due to the potential inhibitory effect of cardamonin on TNF-α, and thus suppressing the production of other pro-inflammatory cytokines such as IL-1β as well as IL-6, which play an important role in the initiation of mechanical hypersensitivity in RA. The current result was supported by Ahmad et al. who reported that cardamonin had successfully suppressed the production of TNF-α in induced RAW cells in a dosedependent manner (Ahmad et al., 2006) . Also, cardamonin was shown to be capable of reducing thermal hyperalgesia in the CFA-induced rat paws in a dose-dependent manner most possibly through inhibiting the pro-inflammatory cytokine TNF-α as it plays an important role in inducing the release of IL-6. IL-6 is able to suppress the inhibitory neurotransmission, concurrently promote the phosphorylation of cAMP response element-binding protein (CREB), which leads to thermal hyperalgesia (Kawasaki et al., 2008) . Similarly, TNF-α and IL-1β are able to potentiate N-methyl-D-aspartate (NMDA)-induced current, while TNF-α alone enhanced α-amino-3-hydroxyl-5methyl-4-isoxazole-propionate (AMPA)-induced current in the dorsal horn neurons (Kawasaki et al., 2008) . The excitatory postsynaptic responses caused by both NMDA and AMPA glutamate receptor activation could lead to hypersensitivity in RA. Therefore, the mechanical allodynia and thermal hyperalgesia experienced by the RA rats were significantly reduced which might partly due to TNF-α, IL-1β and IL-6 suppression by cardamonin. Considering the importance of the early onset in CFAinduced RA in this study, the level of inflammatory cytokines measured at this point would contribute to the role of cardamonin in suppressing the cytokines in the late phase.
Conclusion
The present study demonstrated that repeated administration of cardamonin had significantly reduced CFA-induced inflammatory and nociceptive responses. Further supporting data for anti-arthritic effect of cardamonin was obtained using histological sections which demonstrated that CFA-induced RA joint changes had been significantly inhibited in the cardamonin-treated rats. Based on the present results, cardamonin may be a promising candidate for the long-term treatment of pain and inflammation in RA.
